Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Takara Bio Inc (4974 JP)
Watchlist
53
Analysis
Health Care
•
Japan
TAKARA BIO INC. is a biopharmaceutical company. The Company researches and develops reagents for genome engineering and analysis, technology used for gene therapy, and natural health food products using mushrooms and seaweed body and extracts.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Hisamitsu Pharmaceutical Co
•
15 Feb 2026 15:34
Weekly Deals Digest (15 Feb) - Hisamitsu, Takara Bio, Toyota Ind, Mandom, Dongfeng, Pepper Money
A weekly summary of key developments across ECM and Event-Driven names tracked by us across Hong Kong, Australia, NZ, Singapore, Japan, Indonesia,...
Arun George
Follow
293 Views
Share
bullish
•
Ana Holdings
•
27 Feb 2025 15:46
Quiddity JPX-Nikkei 400 Rebal 2025: End-Feb 2025 Ranks
There are 45 Potential ADDs and 44 Potential DELs (unique names) presented in the current Quiddity Leaderboard. The High and Medium conviction ADDs...
Janaghan Jeyakumar, CFA
Follow
757 Views
Share
bearish
•
Takara Bio Inc
•
22 Feb 2024 09:30
Takara Bio (4974 JP): Limited Upside Potential Amid Poor Financial Result and Bleak Outlook
Takara Bio reports massive declines in sales and profit in 9MFY24, due to decrease of sales of COVID testing reagents. Company anticipates...
Tina Banerjee
Follow
459 Views
Share
bullish
•
Pasona Group
•
19 Nov 2023 07:05
Last Week in Event SPACE: Zhejiang, Pasona, ENN Energy, Asahi Group, Azure Minerals
The weekend is here! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed...
David Blennerhassett
Follow
735 Views
Share
bearish
•
Takara Bio Inc
•
16 Nov 2023 22:39
Takara Bio (4974 JP): Smaller-Than-Expected Decline in H1FY24 Profit; FY24 Guidance Revised Downward
Takara Bio has cut FY24 sales, operating profit, and net profit guidance by 15%, 63%, and 64%, respectively due to anticipated sluggish life...
Tina Banerjee
Follow
662 Views
Share
First
Previous
4
5
6
7
8
9
10
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x